Law360, New York ( January 27, 2015, 10:03 AM EST) -- On Dec. 22, 2014, a federal district court in New Jersey found that Mylan Pharmaceuticals Inc. alleged facts sufficient to plead an antitrust claim under Section 2 of the Sherman Act against defendant, Celgene Corporation, for denying a generic rival access to samples of its branded drugs (Thalomid and Revlimid) that are distributed pursuant to a Risk Evaluation and Mitigation Strategies ("REMS") program....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.